er-086526 and Salivary-Gland-Neoplasms

This study examined the microtubule inhibitor eribulin in recurrent/metastatic salivary gland cancers (RMSGCs), a disease where no therapeutic standard exists.. Between May 2012 and August 2015, 29 patients were enrolled in this study. The median age was 63 years (range 34-75 years) and 20 of the subjects were men (69%). The most common histologies were adenoid cystic carcinoma (ACC; n = 11) and adenocarcinoma (n = 4). Neutropenia was the most common toxicity (grade 3; n = 5; 17% and grade 4 n = 3; 10%). The objective responses were observed in 3 of 29 patients (10%), 20 of 29 patients (69%) demonstrated a decrement in tumor size, and disease control was observed in 26 of 29 patients (90%).. Although the objective responses to eribulin were uncommon, disease control was observed in the majority of patients.

Topics: Adult; Aged; Antineoplastic Agents; Female; Furans; Humans; Ketones; Male; Middle Aged; Neoplasm Recurrence, Local; Salivary Gland Neoplasms; Treatment Outcome

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Furans; Humans; Ketones; Neoplasm Metastasis; Salivary Ducts; Salivary Gland Neoplasms